Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Work In Process (2017 - 2025)

Historic Work In Process for Adma Biologics (ADMA) over the last 9 years, with Q3 2025 value amounting to $44.5 million.

  • Adma Biologics' Work In Process fell 1682.44% to $44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.5 million, marking a year-over-year decrease of 1682.44%. This contributed to the annual value of $61.6 million for FY2024, which is 2422.36% up from last year.
  • As of Q3 2025, Adma Biologics' Work In Process stood at $44.5 million, which was down 1682.44% from $43.2 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Work In Process peaked at $62.1 million during Q1 2023, and registered a low of $43.2 million during Q2 2025.
  • In the last 5 years, Adma Biologics' Work In Process had a median value of $52.3 million in 2022 and averaged $52.9 million.
  • As far as peak fluctuations go, Adma Biologics' Work In Process surged by 9465.87% in 2021, and later tumbled by 2160.2% in 2025.
  • Quarter analysis of 5 years shows Adma Biologics' Work In Process stood at $59.0 million in 2021, then fell by 4.74% to $56.2 million in 2022, then fell by 11.66% to $49.6 million in 2023, then grew by 24.22% to $61.6 million in 2024, then fell by 27.83% to $44.5 million in 2025.
  • Its Work In Process stands at $44.5 million for Q3 2025, versus $43.2 million for Q2 2025 and $49.8 million for Q1 2025.